Advertisement

Pediatric Intracranial Germinomas

  • Jonathan W. Lischalk
  • Shannon M. MacDonaldEmail author
Chapter
Part of the Practical Guides in Radiation Oncology book series (PGRO)

Abstract

  • Epidemiology
    • Intracranial germ cell tumors (IGCT) account for 3–5% of pediatric central nervous system malignancies in the United States, though the incidence can be as high as 10–11% in some Asian countries [1].

  • Demographics
    • Germinomas are most commonly seen in adolescents aged 10–12 years with 90% occurring before age 20 years. A male predominance is noted for IGCTs, in particular for tumors of pineal gland origin [1, 2].

  • Histological subtypes
    • IGCTs are broadly classified by the World Health Organization (WHO) into pure germinomas and non-germinomatous germ cell tumors (NGGCT). The majority, two-thirds, are pure germinomas with the remaining one-third NGGCTs [2].

    • NGGCTs are subclassified into [1] embryonal, [2] yolk sac or endodermal sinus, [3] choriocarcinoma, [4] teratoma (immature, mature, and malignant transformed), and [5] mixed germ cell tumor (farraginous components of NGGCT and pure germinoma) [2].

  • Anatomy and patterns of spread
    • There is an intimate association with midline proximal third ventricular structures, specifically the pineal and suprasellar (e.g., infundibulum and pituitary stalk) regions, which make up nearly two-thirds and one-third of observed IGCTs, respectively. Less common locations include the basal ganglia and thalamus [1, 3].

    • Up to 10% of patients present with bifocal disease, more commonly seen in pure germinomas, which is believed to represent multifocal occurrence of tumors and not metastatic disease. These patients are treated as though they have localized disease [3–5].

    • CSF dissemination occurs in 10–20% of patients [1].

  • Prognosis
    • IGCTs treated with standard therapy demonstrate exceptional long-term disease-free survival of >90% and 70–80% for pure germinomas and NGGCTs, respectively [1].

    • The Japanese Pediatric Brain Tumor Study Group Classification categorizes patients into three prognostic groups based on histology for patients that have resection of tumor up front: [1] “good” with a 10-year survival >90%, [2] “intermediate” with a 3-year survival of ~70%, and [3] “poor” with a 3-year survival 10–30% [6]. In the United States and Europe, it is uncommon to perform surgical resection up front for full pathologic evaluation of the tumor.

References

  1. 1.
    Gunderson LL, Tepper JE, Bogart JA (2015) Clinical radiation oncology, 4th edn. Elsevier Saunders, Philadelphia, PA, p 1648Google Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefGoogle Scholar
  3. 3.
    Goodwin TL, Sainani K, Fisher PG (2009) Incidence patterns of central nervous system germ cell tumors: a SEER study. J Pediatr Hematol 31(8):541–544CrossRefGoogle Scholar
  4. 4.
    Weksberg DC, Shibamoto Y, Paulino AC (2012) Bifocal intracranial germinoma: a retrospective analysis of treatment outcomes in 20 patients and review of the literature. Int J Radiat Oncol Biol Phys 82(4):1341–1351CrossRefGoogle Scholar
  5. 5.
    Jennings MT, Gelman R, Hochberg F (1985) Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 63(2):155–167CrossRefGoogle Scholar
  6. 6.
    Miyanohara O, Takeshima H, Kaji M, Hirano H, Sawamura Y, Kochi M et al (2002) Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors. J Neurosurg 97(1):177–183CrossRefGoogle Scholar
  7. 7.
    Hoffman HJ, Otsubo H, Hendrick EB, Humphreys RP, Drake JM, Becker LE et al (1991) Intracranial germ-cell tumors in children. J Neurosurg 74(4):545–551CrossRefGoogle Scholar
  8. 8.
    Halperin EC, Constine LS, Tarbell NJ, Kun LE (2010) Pediatric radiation oncology, 5th edn. Lippincott Williams and Wilkins, New York, p 512Google Scholar
  9. 9.
    Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garre ML et al (2013) SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-Oncology 15(6):788–796CrossRefGoogle Scholar
  10. 10.
    Shikama N, Ogawa K, Tanaka S, Toita T, Nakamura K, Uno T et al (2005) Lack of benefit of spinal irradiation in the primary treatment of intracranial germinoma: a multiinstitutional, retrospective review of 180 patients. Cancer 104(1):126–134CrossRefGoogle Scholar
  11. 11.
    Rogers SJ, Mosleh-Shirazi MA, Saran FH (2005) Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 6(7):509–519CrossRefGoogle Scholar
  12. 12.
    Bamberg M, Kortmann RD, Calaminus G, Becker G, Meisner C, Harms D et al (1999) Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 17(8):2585–2592CrossRefGoogle Scholar
  13. 13.
    Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S et al (1996) Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The first international central nervous system germ cell tumor study. J Clin Oncol 14(11):2908–2915CrossRefGoogle Scholar
  14. 14.
    Baranzelli MC, Patte C, Bouffet E, Couanet D, Habrand JL, Portas M et al (1997) Nonmetastatic intracranial germinoma: the experience of the French Society of Pediatric Oncology. Cancer 80(9):1792–1797CrossRefGoogle Scholar
  15. 15.
    Afzal S, Wherrett D, Bartels U, Tabori U, Huang A, Stephens D et al (2010) Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. J Neuro-Oncol 97(3):393–399CrossRefGoogle Scholar
  16. 16.
    Robertson PL, DaRosso RC, Allen JC (1997) Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neuro-Oncol 32(1):71–80CrossRefGoogle Scholar
  17. 17.
    Kim JW, Kim WC, Cho JH, Kim DS, Shim KW, Lyu CJ et al (2012) A multimodal approach including craniospinal irradiation improves the treatment outcome of high-risk intracranial nongerminomatous germ cell tumors. Int J Radiat Oncol Biol Phys 84(3):625–631CrossRefGoogle Scholar
  18. 18.
    MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D et al (2011) Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys 79(1):121–129CrossRefGoogle Scholar
  19. 19.
    Acharya S, DeWees T, Shinohara ET, Perkins SM (2015) Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas. Neuro-Oncology 17(5):741–746Google Scholar
  20. 20.
    Odagiri K, Omura M, Hata M, Aida N, Niwa T, Ogino I et al (2012) Treatment outcomes, growth height, and neuroendocrine functions in patients with intracranial germ cell tumors treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys 84(3):632–638CrossRefGoogle Scholar
  21. 21.
    Mabbott DJ, Monsalves E, Spiegler BJ, Bartels U, Janzen L, Guger S et al (2011) Longitudinal evaluation of neurocognitive function after treatment for central nervous system germ cell tumors in childhood. Cancer 117(23):5402–5411CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation MedicineGeorgetown University HospitalWashington, DCUSA
  2. 2.Department of Radiation Oncology, Francis H. Burr Proton Therapy CenterMassachusetts General HospitalBostonUSA

Personalised recommendations